Skip to main content
LIFECOME BIOCHEMISTRY CO., LTD. logo

LIFECOME BIOCHEMISTRY CO., LTD. — Investor Relations & Filings

Ticker · 002868 ISIN · CNE100002QH2 LEI · 65560089EP03NANEN790 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,742 across all filing types
Latest filing 2024-12-10 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 002868

About LIFECOME BIOCHEMISTRY CO., LTD.

https://www.pclifecome.com

Lifecome Biochemistry Co., Ltd. focuses on the research, development, and large-scale production of fermentation-based veterinary pharmaceuticals and feed additives. The company’s core product portfolio includes Bacitracin Zinc, Bacitracin Methylene Disalicylate (BMD), and Colistin Sulfate, available in both active pharmaceutical ingredient (API) and premix forms. These biochemical products are primarily utilized in the livestock and poultry sectors to manage enteric health and improve feed efficiency. The organization operates advanced fermentation and purification facilities, maintaining compliance with international Good Manufacturing Practices (GMP) and various global regulatory standards. By leveraging specialized biotechnological processes, the company provides high-purity solutions aimed at enhancing animal nutrition and disease prevention across international markets.

Recent filings

Filing Released Lang Actions
第五届董事会第八次（临时）会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the company's fifth board of directors' eighth (extraordinary) meeting. It includes information about financing credit limits, guarantees, related party transactions, asset sales, internal audit system revisions, and the scheduling of a shareholders' meeting. The document is not a full financial report but rather a formal disclosure of board decisions and meeting outcomes. It does not contain financial statements or detailed financial analysis, nor is it a transcript or presentation. The content fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors or senior management.
2024-12-10 Chinese
绿康生化股份有限公司拟股权转让涉及的浦城县农村信用合作联社股东部分权益估值项目估值报告
Regulatory Filings
2024-12-10 Chinese
关于控股股东解除融资融券业务的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (486 characters) from a company about its controlling shareholder解除融资融券业务 (termination of margin financing and securities lending business). It details the transfer of shares from a margin account back to a regular securities account and confirms the shareholder's current holdings. There is no financial data, no detailed report, no earnings or management discussion, and no mention of a report being attached or published. This is a regulatory announcement about a financing-related shareholder transaction but not a financing update per se (which would involve new capital raising). It fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other categories.
2024-12-06 Chinese
关于持股5%以上股东协议转让公司股份完成过户登记的公告
Major Shareholding Notification Classification · 100% confidence The document is an announcement regarding the completion of share transfer registration involving shareholders holding more than 5% of the company's shares. It details the transfer of shares between two major shareholders, the completion date of the transfer, and the updated shareholding structure. There is no financial data, earnings information, or management discussion. The document is a formal notification of a change in major shareholding levels, which fits the category of Major Shareholding Notification (MRQ). The document length is short and focused solely on shareholding changes, confirming it is not a full report or financial statement.
2024-11-27 Chinese
关于为全资子公司提供担保的进展公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by a company regarding the progress of guarantees provided to its wholly-owned subsidiary. It details the amounts, terms, and counterparties involved in the guarantee agreements. The document includes financial data of the subsidiary but does not present a comprehensive financial report or audit. It is a specific update on financing-related activities, specifically guarantees provided to subsidiaries, which is a form of capital or financing update. The document length is 3302 characters, which is relatively short and focused on a specific financing matter rather than a full report. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2024-11-07 Chinese
监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a meeting resolution announcement from the Supervisory Board of the company regarding the approval of the 2024 third quarter report. It states that the Supervisory Board reviewed and approved the third quarter report and confirms its accuracy. The document does not contain the actual financial data or the full report itself but refers to the report published elsewhere (on Securities Daily and cninfo website). The document is short (699 characters) and serves as an announcement of the meeting resolution and approval of the quarterly report, not the report itself. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement related to corporate governance and report approval, rather than the Interim/Quarterly Report (IR) which would contain substantive financial data.
2024-10-30 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.